Condition: BCLC Stage B Hepatocellular Carcinoma · BCLC Stage C Hepatocellular Carcinoma · Hepatic Arterial Infusion Chemotherapy · Sponsor: First Hospital of China Medical University
The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular carcinoma (HCC) after failure of systemic therapy recommended by BCLC.
This description comes directly from the study's public registry record.
Jiaxi Liu · +8618940279150 · dmuvictor@163.com
Always discuss trial participation with your own doctor first.
| The first hospital of China medical university | Shenyang, Liaoning, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06632093